[Clinical considerations on the use of a new synthetic androgen, Calusterone, in the treatment of advanced breast cancer].
Results with a new synthetic androgen (Calusterone) in the management of 22 cases of advanced breast cancer are presented. Reference is made to the doses employed, the therapeutic results observed, and the side-effects caused by the drug. By comparison with the literature data, a partial response to treatment was observed in 47% of the series.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008777:Methyltestosterone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis
D008777:Methyltestosterone
Considerazioni cliniche sull'impiego di un nuovo androgeno di sintesi, il Calusterone, nella terapia del cancro della mammella in fase avanzata.